Carelizumab Combined With Regorafenib in the Treatment of HCC（CARE-2020）

Sponsor
Nanfang Hospital, Southern Medical University
Study ID
NCT04806243
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

To investigate the efficacy and safety of carelizumab combined with regorafenib in second-line treatment for patients with primary hepatocellular carcinoma.

Key Dates

Start date
May 6, 2021
Status verified
Apr 2021
Primary completion
Jan 1, 2022
Completion
Jan 1, 2022

Study Design

Enrollment
69 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Carelizumab Combined With Regorafenib arm

Primary Outcome Measure

os（overall survival） [ Time Frame: 21 days ]

Related Studies